<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483366</url>
  </required_header>
  <id_info>
    <org_study_id>163-06</org_study_id>
    <secondary_id>P30CA036727</secondary_id>
    <secondary_id>UNMC-16306</secondary_id>
    <nct_id>NCT00483366</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)</brief_title>
  <official_title>Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and&#xD;
      capecitabine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving imatinib mesylate together with gemcitabine&#xD;
      and capecitabine may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine and&#xD;
      capecitabine when given together with imatinib mesylate in treating patients with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of gemcitabine hydrochloride and capecitabine when&#xD;
           combined with imatinib mesylate in patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Explore the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of gemcitabine and capecitabine.&#xD;
&#xD;
      Patients receive oral imatinib mesylate once daily on days 1-5 and 8-12, gemcitabine&#xD;
      hydrochloride IV on days 3 and 10, and oral capecitabine twice daily on days 1-14. Treatment&#xD;
      repeats every 21 days for at least 2 courses in the absence of progressive disease or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and&#xD;
      capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Existing paraffin-embedded tissue blocks from patients diagnosed with melanoma or renal cell&#xD;
      carcinoma will be assessed for c-kit mutations by polymerase chain reaction and direct&#xD;
      sequencing of both juxtamembrane domains (exons 9 and 11) and tyrosine kinase domain (exon 13&#xD;
      and 17). (Begins 12-11-2008)&#xD;
&#xD;
      PROJECTED ACCRUAL: Closed to patient accrual 12/11/2008.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 29, 2011</completion_date>
  <primary_completion_date type="Actual">January 30, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of gemcitabine hydrochloride and capecitabine when combined with imatinib mesylate</measure>
    <time_frame>By the end of cycle 2</time_frame>
    <description>Cohorts of 3 starting at dose level 0. The imatinib dose is fixed. The dose of capecitabine is initially fixed and the dose of gemcitabine is increased 1 dose level. For the subsequent cohort, the dose of gemcitabine will be fixed and the dose of capecitabine advanced to the next dose level. 3 patients will be treated on the initial schedule. If no dose-limiting toxicities related to drug are observed and no patients require dose mods by the end of cycle 2, then 3 patients will be treated on the next schedule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>By the end of cycle 2.</time_frame>
    <description>Cohorts of 3 starting at dose level 0. The imatinib dose is fixed. The dose of capecitabine is initially fixed and the dose of gemcitabine is increased 1 dose level. For the subsequent cohort, the dose of gemcitabine will be fixed and the dose of capecitabine advanced to the next dose level. 3 patients will be treated on the initial schedule. If no dose-limiting toxicities related to drug are observed and no patients require dose mods by the end of cycle 2, then 3 patients will be treated on the next schedule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Following response assessment.</time_frame>
    <description>Deidentified melanoma samples will be sent to our collaborator at Ohio State, Dr. Christopher Corless, who is a recognized expert in this field. Renal cell samples will be assayed here at our institution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.&#xD;
Dose limiting toxicity (DLT) will be determined after cycle two for each patient.&#xD;
Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14&#xD;
Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2&#xD;
Treatment cycle: 21-days&#xD;
Treatment duration: Until disease progression or unacceptable toxicity defined in protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Dose level Capecitabine&#xD;
-1 400 mg/m2 bid&#xD;
0 500 mg/m2 bid&#xD;
500 mg/m2 bid&#xD;
600 mg/m2 bid&#xD;
600 mg/m2 bid&#xD;
725 mg/m2 bid&#xD;
725 mg/m2 bid&#xD;
850 mg/m2 bid&#xD;
850 mg/m2 bid</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Dose level Gemcitabine&#xD;
-1 400 mg/m2 0 450 mg/m2&#xD;
550 mg/m2&#xD;
550 mg/m2&#xD;
675 mg/m2&#xD;
675 mg/m2&#xD;
825 mg/m2&#xD;
825 mg/m2&#xD;
1000 mg/m2</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Dose level Imatinib&#xD;
-1 400 mg/d 0 400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d&#xD;
400 mg/d</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.</description>
    <arm_group_label>Imatinib/Gemcitabine/Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed solid tumor, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Failed standard therapy and subsequent line therapy&#xD;
&#xD;
               -  Disease for which no standard therapy exists&#xD;
&#xD;
          -  Any number of prior therapies are allowed provided standard treatment options have&#xD;
             either been exhausted or are unable to be administered, in the opinion of the treating&#xD;
             physician&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
               -  Measurable disease is defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm&#xD;
                  by CT scan or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease is defined as all other lesions, including small lesions (&lt;&#xD;
                  20 mm by conventional techniques or &lt; 10 mm by spiral CT scan) and truly&#xD;
                  nonmeasurable lesions, including the following:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  Brain metastases allowed provided both of the following are true:&#xD;
&#xD;
               -  Patient has undergone resection and/or radiotherapy and does not require steroids&#xD;
&#xD;
               -  No evidence of disease progression by CT scan or MRI at least 4 weeks after&#xD;
                  completion of steroids, surgery, and/or radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL (epoetin alfa supplementation allowed)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN) (except if due to Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier method contraception during and for 3&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  Must be able to tolerate oral intake for the administration of imatinib mesylate and&#xD;
             capecitabine&#xD;
&#xD;
          -  No active serious infections&#xD;
&#xD;
          -  No known allergy or hypersensitivity to study drugs or their formulation&#xD;
&#xD;
          -  No comorbidity or condition which, in the opinion of the investigator, would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No other primary malignancy within the past 5 years except basal cell skin cancer,&#xD;
             cervical carcinoma in situ, or another primary malignancy that is not currently&#xD;
             clinically significant or requires active intervention&#xD;
&#xD;
          -  No other malignant disease&#xD;
&#xD;
          -  No New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No known chronic liver disease (e.g., chronic active hepatitis or cirrhosis)&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior treatment with gemcitabine hydrochloride, capecitabine, or imatinib mesylate&#xD;
             allowed provided all three drugs were not used in combination simultaneously&#xD;
&#xD;
          -  Prior radiotherapy allowed provided the lesion treated is not used to assess response&#xD;
             and has not demonstrated progression after treatment&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  More than 4 weeks since prior packed red blood cell transfusions&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent anticoagulation therapy with warfarin&#xD;
&#xD;
               -  Therapeutic anticoagulation with low-molecular weight heparin or heparin allowed&#xD;
&#xD;
               -  Mini-dose warfarin (e.g., 1 mg/day) for prophylaxis of central venous catheter&#xD;
                  thrombosis allowed at the discretion of the treating physician&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy and biologic agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent routine systemic corticosteroid therapy (corticosteroid therapy may only&#xD;
             be administered after consultation with the principal investigator)&#xD;
&#xD;
          -  Concurrent bisphosphonate therapy allowed for skeletal metastases provided therapy is&#xD;
             started before study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Hauke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth C. Reed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Ralph Hauke</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

